AdaptHealth (AHCO) Q3 2026 earnings review
AdaptHealth raises its profit plan, but equipment costs drain cash
AdaptHealth, a provider of home sleep and oxygen equipment, stopped the profit drain on its largest fixed-fee health system contract, but heavy upfront equipment buying still starved the business of cash. Continuing sales rose 11% from a year ago, and chief executive Suzanne Foster lifted the full-year operating cash profit outlook after lower staffing costs pushed the third-quarter margin to 19%. However, the company took another $185 million goodwill write-down and cut its full-year free cash flow plan to $50–75 million.
| Sales from businesses owned a year ago | +12.8% from a year ago |
|---|---|
| Operating cash profit (Adjusted Ebitda) margin | 19.0% 17.8% last quarter; ~17.9% planned |
| Full-year operating cash profit outlook | Raised $12.5M middle of the range: $517.5M |
| Full-year free cash flow outlook | Cut $37.5M middle of the range: $62.5M |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because stabilizing the West Coast contract's operating margin is offset by a second straight cut to full-year cash generation. The good news: beating the third-quarter margin target and raising the full-year profit plan eases the fear that fixed-fee contracts cannot be run profitably, while antitrust clearance keeps the $235 million Diabetes unit sale on track for early 2027. The bad news: nine-month free cash flow sits at just $3 million, and net debt has climbed $162 million this year.
The question now is whether fixed-fee contracts can generate cash after their first year, or if patient demand requires permanent heavy spending on equipment. If equipment purchases normalize once new patients are set up, free cash flow will rebound in 2027; if utilization stays high, cash conversion will remain weak. Fourth-quarter free cash flow, which must reach about $60 million by our math to meet the lowered plan, will provide the next test.
🐂 Bull Case
The Large Fixed-Fee Contract Stopped Draining Profit
AdaptHealth provides home medical equipment such as sleep apnea machines and oxygen tanks. Last quarter, a massive new capitated contract—where AdaptHealth receives a fixed monthly fee per patient regardless of how much equipment they use—ran $15 million over budget on high patient demand and extra staffing. In the third quarter, the home healthcare provider brought those costs under control.
"Our capitated partnership made a positive contribution to enterprise Adjusted EBITDA, driven by a tighter labor model and lower costs to serve," chief executive Suzanne Foster said. Operating cash profit (Adjusted EBITDA, which strips out interest, taxes, depreciation, and one-off charges) reached 19.0% of revenue. That beat the company's 17.9% target and rose 1.2 percentage points from the second quarter. Management raised its full-year operating cash profit outlook by $12.5 million at the middle of the range.
One quarter of sequential improvement fades the contract overrun concern, but it does not settle it. General and administrative overhead fell 1.2 percentage points of revenue from a year ago, to 11.9%, helping offset higher equipment costs. What to watch: fourth-quarter operating cash profit margin, which the full-year outlook puts at 19.2% by our math. Holding above 19% would show the contract is on track for its 20% target in 2027.
New Contracts and App Users Drive 13% Growth
While fixing its largest contract, AdaptHealth kept signing new ones and shifting patients to digital ordering. Sales from businesses it owned a year ago grew 12.8%, with gains across all three continuing segments: Sleep Health, Respiratory Health, and Wellness at Home. The company also cleared the antitrust waiting period to sell its Diabetes Health unit for $235 million in cash, on track for early 2027.
- Continuing revenue: $745.6 million, up 10.9% from a year ago and $15.6 million above the middle of the company's plan
- New agreements: four preferred-provider health system deals and two regional fixed-fee health plan deals
- Digital adoption: 615,000 registered users on myAPP, its patient ordering app, up 88% since year-end 2025
- AI mask-fitting tool: more than 12,600 patient scans completed in the quarter
The digital tools matter because automated resupply and better mask fits reduce costly staff time and returns. What to watch: underlying revenue growth in the first quarter of 2027, once the big West Coast contract passes its one-year mark. Keeping growth in the mid-single digits after that anniversary would prove the new regional deals are adding real volume.
🐻 Bear Case
Equipment Spending Forced Another Free Cash Flow Cut
"The business is stabilizing as we work through a period of transformation, and we look forward to carrying that momentum into 2027," Foster said. Yet for the second quarter in a row, the medical equipment provider had to cut its full-year free cash flow outlook. Management lowered the target to $50–75 million, down from $80–120 million in August and $175–225 million in May.
- Nine-month free cash flow: $2.6 million, down 98% from $140.1 million a year ago
- Nine-month equipment purchases: $393.0 million, up 41% from $278.5 million a year ago
- Net debt including finance leases: $1.84 billion by our math, up $162 million since December 2025
Serving fixed-fee contracts requires buying sleep and oxygen machines upfront while collecting monthly payments over time. Patient equipment depreciation rose 2.0 percentage points of revenue from a year ago, to 15.7%. Because cash generation vanished over the first nine months, AdaptHealth borrowed a net $145 million on its credit lines this year instead of paying down debt. What to watch: fourth-quarter free cash flow, which must reach $60 million by our math to hit the middle of the lowered plan. A shortfall would keep debt leverage well above the company's 2.5x target until the Diabetes sale closes.
Another $185 Million Write-Down Hits Core Units
AdaptHealth took a $184.8 million goodwill write-down in the third quarter because the estimated value of its Respiratory Health and Wellness at Home units fell below their book value. That follows a $144.2 million write-down on the same two businesses in the second quarter, bringing nine-month goodwill charges to $329.0 million and pushing the quarter into a $167.0 million loss from continuing operations.
Even setting aside the write-down and a $12.0 million gain from moving its e-commerce unit into a joint venture, underlying profitability shrank from a year ago. Cost of net revenue—the direct cost of medical supplies, patient equipment depreciation, and field staff—rose 5.2 percentage points of revenue from a year ago, to 84.6%. By our math, operating margin excluding those two one-off items fell from 6.5% a year ago to 2.3%.
What to watch: segment margins for Respiratory Health and Wellness at Home in the third-quarter 10-Q filing, which arrives in November. Another drop in segment profit would leave the remaining $2.16 billion of goodwill on the balance sheet vulnerable to further write-downs.
Risks This Quarter Didn't Answer
The earnings release did not update four standing cost and legal risks that management previously flagged or disclosed in filings.
- Supplier price hike: management promised a third-quarter update on negotiations over a July 1 manufacturer price increase that costs $30 million per half-year; the conference call or 10-Q will show if the hike is permanent.
- Stranded Diabetes overhead: selling Diabetes Health leaves $60 million of corporate overhead behind, with half slated for removal within a year of closing; any progress awaits the call.
- Federal billing investigations: two civil investigative demands on humidifier and respiratory billing remain open; the 10-Q commitments footnote will show if accruals were booked.
- Cybersecurity breach costs: the second-quarter filing noted undetermined legal and notification costs from a patient data breach; the 10-Q will update the financial impact.
👓 Other Themes
AdaptHealth Replaces Its Chief Financial Officer
AdaptHealth replaced finance chief Jason Clemens during the quarter, naming Harriss T. Currie as Chief Financial Officer on the release contact page. The company recorded $1.6 million in severance for Clemens inside its $7.3 million of other non-recurring expenses, alongside $5.1 million in consulting fees for business sales. The change comes one quarter after the company had to slash its full-year profit and cash flow targets.
💲 Other KPIs
Contract liabilities—advance monthly payments from customers and health plans for equipment rentals not yet earned—rose 3.8% from the second quarter and 13.2% since year-end 2025. Because these advance billings convert into revenue over roughly one month, the steady climb points to solid near-term rental revenue.
Money owed by insurers and patients rose 1.4% from the second quarter and 6.7% since December 2025, consuming $25.0 million of operating cash flow over the first nine months. Receivables grew slower than the 10.9% rise in continuing revenue, showing that collections kept pace with billings.
🔮 Guidance
Raised. The middle of the full-year plan moved up $20 million to $2.89 billion. By our math, that leaves $724.2 million for the fourth quarter, down 2.9% from the third quarter's $745.6 million because the company moved its e-commerce unit into a joint venture and exited certain Wellness product lines.
Raised. Management lifted the middle of its operating cash profit plan by $12.5 million to $517.5 million after beating its third-quarter margin target. By our math, the outlook leaves $139.0 million for the fourth quarter, which equals a 19.2% margin on implied fourth-quarter revenue, up from 19.0% in the third quarter.
Cut. Management lowered the middle of the cash flow plan by $37.5 million to $62.5 million, following a $100 million cut last quarter: $200M, $200M, $100M, $62.5M. With only $2.6 million generated in the first nine months, the plan requires $59.9 million in the fourth quarter by our math.
❓ Key Questions
Did AdaptHealth settle the $30 million supplier price dispute?
In August, management promised an update by the end of the third quarter on negotiations with a manufacturer that imposed a July 1 price hike costing $30 million per half-year. The release did not mention whether the increase is now permanent.
Why cut full-year cash flow after beating Q3 targets?
AdaptHealth beat its third-quarter targets for both operating cash profit and free cash flow ($51.1 million vs $50 million planned), yet cut its full-year free cash flow outlook by $37.5 million at the middle of the range. Is fourth-quarter equipment spending spiking again?
What triggered the second write-down in Respiratory and Wellness?
The company took a $184.8 million goodwill write-down on its Respiratory Health and Wellness at Home units just three months after taking a $144.2 million charge on the same units. What lowered their long-term cash flow projections again in the third quarter?
How much fixed-fee revenue did AdaptHealth book in Q3?
The earnings release omitted the segment and revenue-type tables that appear in the quarterly filing. Investors need the third-quarter capitated revenue figure to check whether it held near the second quarter's $103.3 million run-rate.